Overview

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

Status:
Completed
Trial end date:
2013-06-12
Target enrollment:
Participant gender:
Summary
To determined what dose of topotecan can be safely given with daily pazopanib.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Topotecan